| Literature DB >> 34461687 |
Bhavuk Garg1, Nishank Mehta1, Rudra Narayan Mukherjee1, Arun M Swamy1, Burhan S Siamwala1, Garima Malik1.
Abstract
STUDYEntities:
Keywords: Epidemiology; Infections; Pott’s disease; Spinal tuberculosis; Tuberculosis
Year: 2021 PMID: 34461687 PMCID: PMC9066256 DOI: 10.31616/asj.2021.0137
Source DB: PubMed Journal: Asian Spine J ISSN: 1976-1902
Grading of outcome using clinical, radiological, and functional criteria
| Grade | Criteria | ||
|---|---|---|---|
| Clinical | Radiological | Functional | |
| Excellent |
- Compliance to treatment - No/minimal side effects to ATT - Normalization of inflammatory markers at final follow-up |
- Complete radiological resolution of disease on contrast-enhanced MRI and plain radiographs at 12-month follow-up - Post-treatment kyphotic angle <30° (thoracic spine) and <20° (cervical and lumbar spine) |
- Improvement or no worsening of pre-treatment neurological status - 12-month follow-up VAS <2 |
| Good |
- Compliance to treatment - Mild side effects to ATT not necessitating temporary cessation/change of drugs, but needing additional medical management - Normalization of inflammatory markers at final follow-up |
- Complete radiological resolution of disease on contrast-enhanced MRI and plain radiographs at 12-month follow-up - Post-treatment kyphotic angle >30° (thoracic spine) and >20° (cervical and lumbar spine) |
- Improvement or no worsening of pre-treatment neurological status - 12-month follow-up VAS <4 |
| Fair |
- Non-compliance to treatment; treatment default - Severe side effects to ATT necessitating temporary cessation/change of drugs - Raised inflammatory markers at final follow-up |
- Incomplete radiological resolution of disease on contrast-enhanced MRI and plain radiographs at 12-month follow-up |
- Improvement or no worsening of pre-treatment neurological status - 12-month follow-up VAS >4 |
| Poor |
- Clinical deterioration necessitating surgical intervention |
- Radiological deterioration necessitating surgical intervention |
- Worsening of neurological status necessitating surgical intervention |
ATT, anti-tubercular treatment; MRI, magnetic resonance imaging; VAS, Visual Analog Scale.
The ‘grade’ ascribed was in accordance with the lowest of the clinical, radiological, and functional criteria met by the patient. A similar combination of clinical, radiological, and functional criteria has been used to grade final outcomes in previous studies as well [8,9].
Summary of demographic and clinical characteristics of the study population (n=1,652)
| Characteristic | Value |
|---|---|
| Age group (yr) | 32.4 (4–87) |
| <10 | 101 (6.1) |
| 11–20 | 251 (15.2) |
| 21–30 | 551 (33.3) |
| 31–40 | 294 (17.8) |
| 41–50 | 188 (11.4) |
| 51–60 | 130 (7.9) |
| 61–70 | 73 (4.4) |
| 71–80 | 47 (2.8) |
| 81–90 | 17 (1.0) |
| Sex | |
| Male | 875 (53.0) |
| Female | 777 (47.0) |
| Comorbidities/co-existing medical conditions | |
| Diabetes mellitus | 152 (9.2) |
| Hypertension | 195 (11.8) |
| Chronic liver disease | 44 (2.7) |
| Chronic kidney disease | 61 (3.7) |
| Coronary artery disease | 49 (2.9) |
| Cerebrovascular disease | 24 (1.5) |
| Rheumatoid arthritis/ankylosing spondylitis/seronegative spondyloarthropathy | 20 (1.2) |
| HIV co-infection | 19 (1.1) |
| Others | 45 (2.7) |
| Associated pulmonary TB | |
| Active | 69 (4.1) |
| Past history | 101 (6.1) |
| Associated extrapulmonary TB | |
| Active | 4 |
| Past history | 2 |
| Symptoms | |
| Pain (back/neck) | 1,620 (98.1) |
| Pain (radicular) | 196 (11.9) |
| Fever | 551 (33.0) |
| Weight loss | 344 (20.8) |
| Loss of appetite | 368 (22.2) |
| Deformity | 149 (9.0) |
| Mean duration of symptoms (mo) | 4.5±2.9 |
| Neurological status (Kumar-Tuli staging) | |
| No deficit | 1,338 (81.0) |
| Stage-1 | 127 (7.7) |
| Stage-2 | 99 (6.0) |
| Stage-3 | 59 (3.6) |
| Stage-4 | 15 (0.9) |
| Indications for surgery (n=173) | |
| Severe paraplegia at presentation | 74 |
| Worsening neurological status while on ATT | 26 |
| Vertebral destruction/mechanical instability causing intractable pain | 25 |
| Failure of response to conservative treatment at 12–16 weeks | 20 |
| Progressive deformity | 26 |
| Uncertain diagnosis | 2 |
| Surgical approach | |
| Cervical | 22 (anterior) |
| Cervicothoracic | 5 (anterior) |
| Thoracic | 1 (anterior trans-thoracic)57 (posterior) |
| Thoracolumbar | 19 (posterior) |
| Lumbar | 58 (posterior) |
| Lumbosacral | 11 (posterior) |
Values are presented as median (range), number (%), or mean±standard deviation.
HIV, human immunodeficiency virus; TB, tuberculosis; ATT, anti-tubercular treatment.
Smith-Robinson approach.
None of the cases required a manubriotomy/sternotomy.
Anterolateral decompression was done by a posterior midline incision by performing costotransversectomy/trans-facetal approach/trans-pedicular approach.
Anterolateral decompression was done by a posterior midline incision by a transforaminal approach/transverse process osteotomy.
Summary of imaging characteristics of the study population
| Variable | Value |
|---|---|
| Regional distribution | |
| Craniocervical (occiput–C2) | 18 (1.1) |
| Cervical (C2/C3 disc–C6/C7 disc) | 227 (13.7) |
| Cervicothoracic (C7–T1/T2 disc) | 18 (1.1) |
| Thoracic (T2–T11) | 439 (26.6) |
| Thoracolumbar (T11/12 disc–L1) | 169 (10.2) |
| Lumbar (L1/L2 disc–L4/L5 disc) | 611 (37.0) |
| Lumbosacral (L5–S1) | 199 (12.0) |
| Sacrum (below S1) and coccyx | 11 (0.7) |
| Morphology of lesion | |
| Paradiscal | 1,354 (82.0) |
| Central | 250 (15.1) |
| Appendiceal | 48 (2.9) |
| No. of levels involved | |
| 1 | 1,338 (81.0) |
| 2 | 199 (12.0) |
| ≥3 | 115 (7.0) |
| Non-contiguous, multifocal involvement/skip lesions | 46 (2.8) |
Values are presented as number (%).
Upper thoracic (T2–T4)=54; middle thoracic (T4/5 disc–T8)=119; and lower thoracic (T8/T9 disc–T11)=266.
A classical paradiscal lesion involving the adjacent end-plates of two contiguous vertebrae was considered as a single level involvement.
Summary of laboratory findings in the study population
| Investigation | Positive | Negative |
|---|---|---|
| LJ medium culture | 19 (2.8) | 648 (91.2) |
| Presence of acid-fast bacilli on Ziehl Neelsen staining | 37 (5.5) | 630 (94.5) |
| Xpert TB assay | 367 (55.0) | 300 (45.0) |
| Rifampicin resistance on Xpert TB assay | 44 (MDR+) | 323 |
| Histopathological features suggestive of TB | 267 (40.0) | 400 (60.0) |
| ESR ≤20 mm/hr | 365 (22.0) | 1,287 (78.0) |
| CRP ≤5 mg/L | 455 (27.5) | 1,197 (72.5) |
Values are presented as number (%).
TB, tuberculosis; MDR, multi-drug resistant; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Test was performed only in 667 patients who underwent transpedicular biopsy; percentages have been reported accordingly.
Reference range for: ESR: <10 mm/hr (males), <20 mm/hr (females); CRP ≤5 mg/L.
Outcome measures at different time-points in the study population who completed final FU (n=1,612)
| Outcome measure | At presentation | 3-mo FU | 12-mo FU | ||
|---|---|---|---|---|---|
| Visual Analog Scale | 8.2±2.9 | 4.7±1.1 | 0.045 | 1.1±0.8 | 0.009 |
| SF-36 | |||||
| PF | 54.4±9.6 | 62.6±9.6 | 0.11 | 78.8±10.2 | 0.023 |
| RP | 38.6±7.6 | 54.8±8.6 | 0.048 | 70.7±11.7 | 0.018 |
| BP | 24.8±6.6 | 45.6±7.8 | 0.045 | 80.1±10.8 | 0.008 |
| GH | 58.6±8.0 | 69.6±9.6 | 0.19 | 80.2±12.2 | 0.012 |
| VT | 60.8±8.0 | 69.9±10.1 | 0.11 | 84.8±9.6 | 0.033 |
| SF | 48.5±7.6 | 54.8±7.8 | 0.22 | 75.5±9.7 | 0.032 |
| RE | 48.2±8.6 | 64.8±9.7 | 0.048 | 78.8±12.2 | 0.021 |
| MH | 55.8±8.7 | 64.4±8.8 | 0.09 | 78.8±11.4 | 0.029 |
| Erythrocyte sedimentation rate (mm/hr) | 54 (4–124) | 42 (1–78) | 0.11 | 12 (1–36) | 0.02 |
| C-reactive protein (mg/L) | 60 (6–119) | 14 (0.1–78) | 0.03 | 5 (0.1–32) | 0.012 |
Values are presented as mean±standard deviation or median (range). Overall outcome grading: excellent: 970 (60.2%); good: 393 (24.4%); fair: 147 (9.1%); and poor: 102 (6.3%). The SF-36 consists of eight domains: PF, RP, BP, GH, VT, SF, RE, and MH.
FU, follow-up; SF-36, 36-Item Short Form Health Survey; PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role-emotional; MH, mental health.
Representing comparison of outcomes between “at presentation” and 3-month FU.
Representing comparison of outcomes between “at presentation” and 12-month FU.
Comparison of demographic characteristics of various studies reporting on epidemiology of spinal tuberculosis
| Authors (year) | Country | Studyperiod | No. ofhospitals | No.of patients | Mean age(yr) | Sex ratio (male:female) | Time from symptom onset to diagnosis (range) |
|---|---|---|---|---|---|---|---|
| Pertuiset et al. [ | France | 1980–1994 | 7 | 103 | 41 | 1.94:1 | 4 mo (1 wk–3 yr) |
| Turgut [ | Turkey | 1985–1996 | Multiple | 694 | 32.4 | 0.98:1 | NR |
| Sakho et al. [ | Senegal | 1986–1998 | 3 | 255 | 34.9 | 1.14:1 | 10.7 mo (1 mo–10 yr) |
| Godlwana et al. [ | South Africa | 2005–2006 | 1 | 104 | NR | 1.36:1 | NR |
| Wang et al. [ | China | 2004–2010 | 1 | 284 | 38 | 1.07:1 | 18.0 mo (3 day–360 mo) |
| Garza Ramos et al. [ | USA | 2002–2011 | Multiple | 2,789 | 51 | 1.56:1 | NR |
| Liu et al. [ | China | 2007–2016 | Multiple | 1,378 | 43.7 | 1.40:1 | 16 mo (15 day–240 mo) |
| Our study | India | 2014–2018 | 1 | 1,652 | 32.4 | 1.12:1 | 4.5 mo (15 day–11 mo) |
NR, not reported.
Comparison of clinical and radiological findings of various studies reporting of epidemiology of spinal TB
| Authors (year) | Most commonpresenting symptom (%) | Patients with neurological deficit at presentation (%) | Patients with HIV infection (%) | Patients with concomitant pulmonary TB (%) | Most common levelof involvement | Patients who had surgicalintervention (%) | Multi-level involvement (%) | Skip lesions (%) |
|---|---|---|---|---|---|---|---|---|
| Pertuiset et al. [ | Back pain (97) | 50 | 0 | 18 | Lumbar | 25 | 25 | 6 |
| Turgut [ | Neurological deficit (69) | 69 | NR | 45 | Thoracic | 98 | NR | 0.3 (single patient) |
| Sakho et al. [ | Back pain (91) | 79 | 2.7 | 59 | Thoracic | 15 | NR | NR |
| Godlwana et al. [ | NR | 56 | 28 | 100 | Thoracic | NR | NR | NR |
| Wang et al. [ | Back pain (92) | 22 | 0 | 12.7 | Thoracic=lumbar | 82 | 27 | 5.6 |
| Garza Ramos et al. [ | NR | NR | 4 | NR | NR | 22 | NR | NR |
| Liu et al. [ | Back pain (92) | 50 | 0 | 26 | Lumbar | 72 | 23 | NR |
| Our study | Back pain (98) | 19 | 1.1 | 4.1 | Lumbar | 10.5 | 19 | 2.8 |
TB, tuberculosis; HIV, human immunodeficiency virus; NR, not reported.
Only includes patients with active concomitant pulmonary TB. Another 6.1% patients had a past history of pulmonary TB.